Johnson & Johnson Vor Biopharma Inc. Call Options Transaction History
Johnson & Johnson
- $290 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VOR
# of Institutions
70Shares Held
48MCall Options Held
1.5KPut Options Held
0-
Ra Capital Management, L.P. Boston, MA22.7MShares$18.2 Million0.34% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.46MShares$5.17 Million0.26% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA6.36MShares$5.09 Million2.98% of portfolio
-
Laurion Capital Management LP New York, NY2.53MShares$2.02 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.56 Million0.0% of portfolio
About Vor Biopharma Inc.
- Ticker VOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,056,300
- Market Cap $30.4M
- Description
- Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...